Pharma

Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more

Check out this week’s medical marketing news, dealmaking and industry chatter.

Lola Offenback

June 20, 2025

8:00 am

美女免费一级视频在线观看

Deals:

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC.

Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Supernus Pharmaceuticals acquired Sage Therapeutics in a $795 million deal.

Processa Pharmaceuticals entered into a binding term sheet with Intact Therapeutics for an exclusive option to license PCS12852 in a deal that includes $452.5 million in total milestone payments.

RNA biotech Ethris announced a strategic collaboration with Thermo Fisher Scientific.

Lisata Therapeutics and GATC Health announced a strategic alliance.

Synfini and O2nix Bio announced a strategic collaboration to develop novel cancer therapeutics targeting FTSJ1.

FDA:

Dyne Therapeutics received FDA clearance to seek accelerated approval for its drug to treat myotonic dystrophy type 1.

The FDA announced the new Commissioner’s National Priority Voucher program that allows companies to shorten the review period of new drugs from 10-12 months to one to two.

The FDA missed a deadline for deciding whether to approve a drug for a potentially life-threatening disorder because of “heavy workload and limited resources,” manufacturer KalVista Pharmaceuticals said.

The agency approved Merck’s Keytruda for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of at least 1.

BioAegis Therapeutics received an FDA Fast Track Designation for recombinant human gelsolin for the treatment of acute respiratory distress syndrome.

The FDA’s Office of Prescription Drug Promotion issued a warning letter to Sprout Pharmaceuticals to express concerns over an Instagram post from Sprout’s CEO about Addyi, the company’s prescription pill for hypoactive sexual desire disorder in women.

UroGen won the FDA’s approval for its intravesical drug mitomycin for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.

FDA granted an Orphan Drug Designation to Medicovestor’s first-in-class ADC for pancreatic cancer.

The FDA approved CSL Behring’s new drug Andembry, which treats hereditary angioedema.

Funding rounds:

Sanofi successfully priced a €1.5 billion bond issue.

Sanofi-backed Welsh biotech Draig Therapeutics secured $140 million in funding.

A group of biopharma investors put $66 million into a San Diego startup called Actio Biosciences.

SwordHealth will expand into the mental health market with a $40 million funding round from General Catalyst.

Arima Genomics closed a $22 million Series C financing round led by Illumina Ventures.

Processa Pharmaceuticals priced its $7 million public offering.

Alzamend Neuro completed the closing of its $5 million private placement.

Layoffs:

Vertex Pharmaceuticals laid off 125 of its employees after a failed type 1 diabetes cell therapy study and consolidation of its office locations.

Prothena plans “substantial” layoffs after a failed phase 3 trial of anti-amyloid antibodies in AL amyloidosis patients.

Industry news:

The Supreme Court upheld a Tennessee law prohibiting gender affirming care for minors in a 6-3 vote.

A $7.4 billion opioid settlement with Purdue Pharma has been approved by all 50 states and U.S. territories.

Lilly announced it will begin selling the two strongest dosages of its weight loss drug Zepbound on its website, regardless of insurance.

Anne Wojcicki regained control of 23andMe, the company she co-founded and led as CEO, through her nonprofit TTAM with a $305 million bid.

Stagwell launched the Stagwell News Network.

A federal judge deemed that some of the grant terminations by the National Institutes of Health are “void and illegal” in a hearing for two lawsuits against the Trump administration.

Sarepta Therapeutics paused its clinical trial and shipments of its gene therapy drug Elevidys after a second patient death.

AbbVie announced a setback in phase 3 of its blood cancer treatment trial testing the drug Venclexta.

However, AbbVie‘s migraine drug met its main goal in head-to-head study with topiramate.

Immuneering’s oral MEK inhibitor allowed 94% of first-line pancreatic cancer patients in a Phase 2a trial to survive six months.

Dupixent bested Xolair in the first head-to-head respiratory trial between the two treatments.

Xaira Therapeutics announced the release of its X-Atlas/Orion AI model, designed for data generation.

See last week’s edition of Rx Rundown.

Related Articles
MM+M Media Summit 2025

Now in its fourth year, the MM+M Media Summit brings together trailblazers from across health media and pharma marketing for a full day of bold, forward-looking conversations.

From Our Partners

Partner Content

Places to Be 2024

Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.

Partner Content

Turning nudges into big wins in point-of-care marketing

How artificial intelligence can deliver more meaningful business outcomes for marketers.

Partner Content

For pharma brands, streaming is critical for awareness

By leveling up their streaming campaigns, advertisers can achieve big lifts in awareness and sales of their medications among all demographics.

Partner Content

HCG: Accelerating the impact of your science

In a world where healthcare is moving fast, HCG is moving faster. Always ahead of the curve, HCG is spearheading the charge to turn scientific potential into real-world impact.

The song grew faint and louder again, then ceased, and she took her hand off his arm. "By-and-by the Tartars did come in reality, and the signal was sent out again. But this time no army came, nor did a single general turn his face to Pekin. The city fell into the hands of the invaders, and they are there to-day. So much for what a woman did; but it sounds too much like the story of 'The Boy and the Wolf' to be true. I stood equally amazed and alert. The voices still growled in the next room, and my horse's bridle still hung before the window. I peered out; there stood the priceless beast. I came a sly step nearer, and lo! in his shadow, flattened against the house, face outward, was Coralie Rothvelt comically holding the forked stick at a present-arms. Throbbing with a grateful, craving allegiance, I seized the rein. Then I bent low out the window and with my free hand touched her face as it turned upward into a beam of moonlight. She pressed my fingers to her lips, and then let me draw her hand as far as it could come and cover it with kisses. Then she drew me down and whispered "You'll do what I've asked?" His lodgings were situated at the lower end of the town. The accommodation consisted[Pg 64] of a small bedroom, which he shared with a fellow clerk, and a place at table with the other inmates of the house. The street was very dirty, and Mrs. Flack's house alone presented some sign of decency and respectability. It was a two-storied red brick cottage. There was no front garden, and you entered directly into a living room through a door, upon which a brass plate was fixed that bore the following announcement:— "Meanwhile the clouds were gathering around you. Prout finds your husband's brother by a happy chance. Once he has done this, things become easy for us. The more easy they become for us the more desperate they grow for you. Then you decide that you must recover those notes from Isidore. You take out your motor car, so cunningly disguised in blacklead----" it makes the fourth time. No doubt about it, Daddy, goods are not High in the air, in the first mausoleum, at the head and foot of the white marble cenotaph, covered with letters that look like creepers, are tablets bearing inscriptions which record the life of the hero; and above the sarcophagus rises an almost impossibly light and airy structure—a canopy of white marble supported on columns as slender as flower-stems. And the Indian may be trusted to know of these. Here where the jacales clustered, there was grass and wood and water that might last indefinitely. The fortifications of Nature had been added to those of Nature's man. It was a stronghold. "Certainly," said the Surgeon, stopping on his way. "I guess I can spare a minute. Take off that bandage, my boy." MRS. GORDON: Not those poor things. They're slaves. He left the post with a great oath in his heart, and a thin trickle of blood on his chin. That summer old Mrs. Backfield became completely bedridden. The gratefulness of sunshine to her old bones was counteracted by the clammy fogs that streamed up every night round the farm. It was an exceptionally wet and misty summer—a great deal of Reuben's wheat rotted in the ground, and he scarcely took any notice when Tilly announced one morning that grandmother was too ill to come downstairs. Merritt presently departed; and at eight the two confederates again met. Soon a compact and resolute body of more than twenty men slowly and cautiously proceeded to the castle, and, in double file, ensconced themselves close to the walls, and so contiguous to the gate of usual egress as to be ready to rush in at the first opening. They had stood thus, scarcely drawing breath, for about half an hour; and Merritt, who, with the smith, was at the head of the little band, was about to propose that they should attempt to force an entrance, when the gate opened, and John Byles, who had been engaged upon some business with Calverley, unsuspectingly issued forth. HoME 美女免费一级视频在线观看 ENTER NUMBET 0018715524.com.cn
ugifts.com.cn
www.kgem.net.cn
hrsolution.com.cn
www.rbxeb.com.cn
midicafe.com.cn
www.b030.com.cn
www.cnzhongzhu.com.cn
green17.com.cn
qhdar.com.cn

美女免费一级视频在线观看

HAYMARKET MARKETING COMMUNICATIONS:

HAYMARKET MARKETING COMMUNICATIONS:

Quick Links

Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more

美女免费一级视频在线观看

Deals:

FDA:

Funding rounds:

Layoffs:

Industry news:

MM+M Media Summit 2025

From Our Partners

Partner Content

Places to Be 2024

Partner Content

Turning nudges into big wins in point-of-care marketing

Partner Content

For pharma brands, streaming is critical for awareness

Partner Content

HCG: Accelerating the impact of your science

美女免费一级视频在线观看

Quick Links

美女免费一级视频在线观看

Deals:

FDA:

Funding rounds:

Layoffs:

Industry news:

Related Articles

MM+M Media Summit 2025

From Our Partners

Partner Content

Places to Be 2024

Partner Content

Turning nudges into big wins in point-of-care marketing

Partner Content

For pharma brands, streaming is critical for awareness

Partner Content

HCG: Accelerating the impact of your science